Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-23T05:00:27.551Z Has data issue: false hasContentIssue false
  • English
  • Français

The Diagnostic Apathia Scale predicts a dose–remission relationship of T-PEMF in treatment-resistant depression

Published online by Cambridge University Press:  02 October 2014

Per Bech ,
Marianne Lunde ,
Lise Lauritzen ,
Birgit Straasø ,
Lone Lindberg ,
Maj Vinberg ,
Mogens Undén ,
Lone Christina Hellström ,
Steen Dissing  and
Erik Roj Larsen
Per Bech*
Affiliation:
Psychiatric Research Unit, Psychiatric Centre North Zealand, Copenhagen University Hospital, Hillerød, Denmark
Marianne Lunde
Affiliation:
Psychiatric Research Unit, Psychiatric Centre North Zealand, Copenhagen University Hospital, Hillerød, Denmark
Lise Lauritzen
Affiliation:
Psychiatric Research Unit, Psychiatric Centre North Zealand, Copenhagen University Hospital, Hillerød, Denmark
Birgit Straasø
Affiliation:
Psychiatric Research Unit, Psychiatric Centre North Zealand, Copenhagen University Hospital, Hillerød, Denmark
Lone Lindberg
Affiliation:
Psychiatric Research Unit, Psychiatric Centre North Zealand, Copenhagen University Hospital, Hillerød, Denmark
Maj Vinberg
Affiliation:
Department of Psychiatry, Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
Mogens Undén
Affiliation:
Psychiatric Research Unit, Psychiatric Centre North Zealand, Copenhagen University Hospital, Hillerød, Denmark
Lone Christina Hellström
Affiliation:
Psychiatric Research Unit, Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen NV, Denmark
Steen Dissing
Affiliation:
Department of Cellular and Molecular Medicine, Panum institute, University of Copenhagen, Copenhagen, Denmark
Erik Roj Larsen
Affiliation:
Department of Affective Disorders, Mood Disorders Research Unit, Aarhus University Hospital, Aarhus, Denmark
*
Per Bech, Psychiatric Research Unit, Psychiatric Centre North Zealand, University of Copenhagen, Dyrehavevej 48, DK-3400 Hillerød, Denmark. Tel: +45 38 64 30 95; Fax: +45 48 26 38 77; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

The aim of this study was to evaluate the predictive validity of the apathy subsyndrome in patients with therapy-resistant depression in the dose–remission study with transcranial pulsating electromagnetic fields (T-PEMF).

Methods

The apathy subsyndrome consists of the symptoms of fatigue, concentration and memory problems, lack of interests, difficulties in making decisions, and sleep problems. We evaluated 65 patients with therapy-resistant depression. In total, 34 of these patients received placebo T-PEMF in the afternoon and active T-PEMF in the morning, that is, one daily dose. The remaining 31 patients received active T-PEMF twice daily. Duration of treatment was 8 weeks in both groups. The Hamilton Depression Scale (HAM-D17) and the Bech-Rafaelsen Melancholia Scale (MES) were used to measure remission. We also focused on the Diagnostic Apathia Scale, which is based on a mixture of items from the MINI and the HAM-D17/MES.

Results

In patients without apathy, the remission rate after T-PEMF was 83.9% versus 58.8% in patients with apathy (p≤0.05). In patients without apathy receiving one active dose daily 94.4% remitted versus 50% for patients with apathy (p≤0.05). In patients without apathy who received two active doses 69.9% remitted versus 66.7% for patients with apathy (p≤0.05).

Conclusion

Taking the baseline diagnosis of the apathy syndrome into consideration, we found that in patients without apathy one daily dose of T-PEMF is sufficient, but in patients with apathy two daily doses are necessary. Including the apathy syndrome as predictor in future studies would seem to be clinically relevant.

Keywords

apathydepressive disorderpredictive value of teststranscranial pulsating electromagnetic fieldstreatment-resistant depression
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 27 , Issue 1 , February 2015 , pp. 1 - 7
Copyright
© Scandinavian College of Neuropsychopharmacology 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Martiny, K, Lunde, M, Bech, P. Transcranial low voltage pulsed electromagnetic fields in patients with treatment-resistant depression. Biol Psychiatry 2010;68:163–169.Google Scholar
2.Straasø, B, LauritZen, L, Lunde, Met al. Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: a randomized, double-blind controlled study. Acta Neuropsychiatrica 2014: doi:10.1017/neu.2014.5.Google Scholar
3.Frank, E, Prien, RF, Jarrett, RBet al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851–855.Google Scholar
4.Bech, P, Kastrup, M, Rafaelsen, OJ. Mini-compendium of rating scales for states of anxiety, depression, mania, and schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl 1986;326:1–37.Google Scholar
5.Andreasson, K, Liest, V, Lunde, Met al. Identifying patients with therapy-resistant depression by using factor analysis. Pharmacopsychiatry 2010;43:252–256.CrossRefGoogle ScholarPubMed
6.Radakovic, R, Abrahams, S. Developing a new apathy measurement scale: Dimensional Apathy Scale. Psychiatry Research 2014;219:658–663.Google Scholar
7.Hellström, LC, Eplov, LF, Nordentoft, M, Ostergaard, SD, Bech, P. The Apathia Scale predicts the ability to return to work. Acta Neuropsychiatrica 2014. doi:10.1017/neu.2014.23.Google Scholar
8.Bech, P, Lauritzen, L, Lunde, Met al. Psychometric analysis of the Melancholia Scale in trials with non-pharmacological augmentation of patients with therapy-resistant depression. Acta Neuropsychiatr 2014;26:155–160.CrossRefGoogle ScholarPubMed
9.Sackeim, HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl. 16):10–17.Google Scholar
10.Bech, P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002;106:252–264.Google Scholar
11.Marin, RS, Biedrzycki, RC, Firinciogullari, S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143–162.Google Scholar
12.Rahbek, UL, Tritsaris, K, Dissing, S. Interactions of low-frequency, pulsed electromagnetic fields with living tissue: biochemical responses and clinical results. Oral Biosci Med 2005;2:29–40.Google Scholar